A COST-UTILITY ANALYSIS OF DEGARELIX IN THE TREATMENT OF ADVANCED HORMONE-DEPENDENT PROSTATE CANCER IN SCOTLAND

被引：1
作者：
Fisher, D. [1 ]
Brereton, N. J. [1 ]
Kildegaard Nielsen, S. [2 ]
Tate, E. [3 ]
机构：
[1] BresMed Hlth Solut, Sheffield, S Yorkshire, England
[2] Ferring Int Ctr SA, St Prex, Switzerland
[3] Hayward Med Commun, Newmarket, Suffolk, England
来源：
VALUE IN HEALTH | 2011年 / 14卷 / 07期
关键词：
D O I：
10.1016/j.jval.2011.08.1201
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A452 / A452
页数：1
相关论文
共 50 条
  • [31] A cost-utility analysis of apalutamide for the treatment of patients with metastatic castration-sensitive prostate cancer (mCSPC).
    Parmar, Ambika
    Timilshina, Narhari
    Emmenegger, Urban
    Alibhai, Shabbir M. H.
    Smoragiewicz, Martin
    Sander, Beate
    Chan, Kelvin K.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [32] Exercise in preventing falls for men with prostate cancer: a modelled cost-utility analysis
    Kim Edmunds
    Paul Scuffham
    Robert U. Newton
    Daniel A. Galvão
    Haitham Tuffaha
    Supportive Care in Cancer, 2022, 30 : 5037 - 5046
  • [33] A cost-utility analysis of apalutamide for metastatic castration-sensitive prostate cancer
    Parmar, Ambica
    Timilshina, Narhari
    Emmenegger, Urban
    Smoragiewicz, Martin
    Sander, Beate
    Alibhai, Shabbir
    Chan, Kelvin K. W.
    CUAJ-CANADIAN UROLOGICAL ASSOCIATION JOURNAL, 2022, 16 (03): : E126 - E131
  • [34] Exercise in preventing falls for men with prostate cancer: a modelled cost-utility analysis
    Edmunds, Kim
    Scuffham, Paul
    Newton, Robert U.
    Galvao, Daniel A.
    Tuffaha, Haitham
    SUPPORTIVE CARE IN CANCER, 2022, 30 (06) : 5037 - 5046
  • [35] COST-UTILITY ANALYSIS OF THE PROLARIS TEST FOR PROSTATE CANCER IN PATIENTS WITH A POSITIVE BIOPSY
    Dragomir, A.
    Prevost, N.
    Aprikian, A.
    Vanhuyse, M.
    Cury, F.
    Kassouf, W.
    VALUE IN HEALTH, 2017, 20 (05) : A249 - A249
  • [36] Cost-utility analysis of 5-fluorouracil and capecitabine for adjuvant treatment in locally advanced rectal cancer
    Katanyoo, Kanyarat
    Chitapanarux, Imjai
    Tungkasamit, Tharatorn
    Chakrabandhu, Somvilai
    Chongthanakorn, Marisa
    Jiratrachu, Rungarun
    Kridakara, Apiradee
    Townamchai, Kanokpis
    Muangwong, Pooriwat
    Tovanabutra, Chokaew
    Chomprasert, Kittisak
    JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2018, 9 (03) : 425 - 434
  • [37] Cost-utility analysis of paclitaxel in combination with cisplatin for patients with advanced ovarian cancer
    Ortega, A
    Dranitsaris, G
    Sturgeon, J
    Sutherland, H
    Oza, A
    GYNECOLOGIC ONCOLOGY, 1997, 66 (03) : 454 - 463
  • [38] Cost-utility analysis of levodopa carbidopa intestinal gel (Duodopa) in the treatment of advanced Parkinson's disease in patients in Scotland and Wales
    Kalabina, Svetlana
    Belsey, Jonathan
    Pivonka, Dominic
    Mohamed, Biju
    Thomas, Chris
    Paterson, Brian
    JOURNAL OF MEDICAL ECONOMICS, 2019, 22 (03) : 215 - 225
  • [39] Cost-utility analysis of palliative care in patients with advanced cancer: a retrospective study
    Hao Wu
    Ping Lin
    Shujuan Yang
    Wei Zhang
    Wenjuan Tao
    BMC Palliative Care, 20
  • [40] Cost-utility analysis of chemotherapy in symptomatic advanced nonsmall cell lung cancer
    Dooms, CA
    Lievens, YN
    Vansteenkiste, JF
    EUROPEAN RESPIRATORY JOURNAL, 2006, 27 (05) : 895 - 901
12345